This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, S.-H. Articles by Li, X.-J. Search for Related Content PubMed PubMed Citation Articles by Li, S.-H. Articles by Li, X.-J.

Next Article 

Molecular and Cellular Biology, March 2002, p. 1277-1287, Vol. 22, No. 5
0270-7306/02/$04.00+0     DOI: 10.1128/MCB.22.5.1277-1287.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Interaction of Huntington Disease Protein with Transcriptional Activator Sp1

Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia 30322

Received 2 October 2001/ Returned for modification 8 November 2001/ Accepted 27 November 2001

Polyglutamine expansion causes Huntington disease (HD) and at least seven other neurodegenerative diseases. In HD, N-terminal fragments of huntingtin with an expanded glutamine tract are able to aggregate and accumulate in the nucleus. Although intranuclear huntingtin affects the expression of numerous genes, the mechanism of this nuclear effect is unknown. Here we report that huntingtin interacts with Sp1, a transcription factor that binds to GC-rich elements in certain promoters and activates transcription of the corresponding genes. In vitro binding and immunoprecipitation assays show that polyglutamine expansion enhances the interaction of N-terminal huntingtin with Sp1. In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin. Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells. Overexpression of Sp1 reduces the cellular toxicity and neuritic extension defects caused by intranuclear mutant huntingtin. These findings suggest that the soluble form of mutant huntingtin in the nucleus may cause cellular dysfunction by binding to Sp1 and thus reducing the expression of Sp1-regulated genes.

This article has been cited by other articles:

• Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., Geschwind, D. H., Gottesfeld, J. M. (2008). The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. USA 105: 15564-15569 [Abstract] [Full Text]  
• Friedman, M. J., Wang, C.-E., Li, X.-J., Li, S. (2008). Polyglutamine Expansion Reduces the Association of TATA-binding Protein with DNA and Induces DNA Binding-independent Neurotoxicity. J. Biol. Chem. 283: 8283-8290 [Abstract] [Full Text]  
• Shao, J., Diamond, M. I. (2007). Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 16: R115-R123 [Abstract] [Full Text]  
• Chiang, M.-C., Juo, C.-G., Chang, H.-H., Chen, H.-M., Yi, E. C., Chern, Y. (2007). Systematic Uncovering of Multiple Pathways Underlying the Pathology of Huntington Disease by an Acid-cleavable Isotope-coded Affinity Tag Approach. Mol. Cell. Proteomics 6: 781-797 [Abstract] [Full Text]  
• Ryu, H., Lee, J., Hagerty, S. W., Soh, B. Y., McAlpin, S. E., Cormier, K. A., Smith, K. M., Ferrante, R. J. (2006). ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. USA 103: 19176-19181 [Abstract] [Full Text]  
• Goswami, A., Dikshit, P., Mishra, A., Nukina, N., Jana, N. R. (2006). Expression of Expanded Polyglutamine Proteins Suppresses the Activation of Transcription Factor NF{kappa}B. J. Biol. Chem. 281: 37017-37024 [Abstract] [Full Text]  
• Cornett, J., Smith, L., Friedman, M., Shin, J.-Y., Li, X.-J., Li, S.-H. (2006). Context-dependent Dysregulation of Transcription by Mutant Huntingtin. J. Biol. Chem. 281: 36198-36204 [Abstract] [Full Text]  
• Mao, X., Moerman-Herzog, A. M., Wang, W., Barger, S. W. (2006). Differential Transcriptional Control of the Superoxide Dismutase-2 {kappa}B Element in Neurons and Astrocytes. J. Biol. Chem. 281: 35863-35872 [Abstract] [Full Text]  
• Lee, J., Kosaras, B., Aleyasin, H., Han, J. A., Park, D. S., Ratan, R. R., Kowall, N. W., Ferrante, R. J., Lee, S. W., Ryu, H. (2006). Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response. FASEB J. 20: 2375-2377 [Abstract] [Full Text]  
• Davies, J E, Rubinsztein, D C (2006). Polyalanine and polyserine frameshift products in Huntington's disease. J. Med. Genet. 43: 893-896 [Abstract] [Full Text]  
• Riley, B. E., Orr, H. T (2006). Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle.. Genes Dev. 20: 2183-2192 [Abstract] [Full Text]  
• Qiu, Z., Norflus, F., Singh, B., Swindell, M. K., Buzescu, R., Bejarano, M., Chopra, R., Zucker, B., Benn, C. L., DiRocco, D. P., Cha, J.-H. J., Ferrante, R. J., Hersch, S. M. (2006). Sp1 Is Up-regulated in Cellular and Transgenic Models of Huntington Disease, and Its Reduction Is Neuroprotective. J. Biol. Chem. 281: 16672-16680 [Abstract] [Full Text]  
• Ying, M., Xu, R., Wu, X., Zhu, H., Zhuang, Y., Han, M., Xu, T. (2006). Sodium Butyrate Ameliorates Histone Hypoacetylation and Neurodegenerative Phenotypes in a Mouse Model for DRPLA. J. Biol. Chem. 281: 12580-12586 [Abstract] [Full Text]  
• Arango, M., Holbert, S., Zala, D., Brouillet, E., Pearson, J., Regulier, E., Thakur, A. K., Aebischer, P., Wetzel, R., Deglon, N., Neri, C. (2006). CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity.. J. Neurosci. 26: 4649-4659 [Abstract] [Full Text]  
• Bae, B.-I., Hara, M. R., Cascio, M. B., Wellington, C. L., Hayden, M. R., Ross, C. A., Ha, H. C., Li, X.-J., Snyder, S. H., Sawa, A. (2006). Mutant Huntingtin: Nuclear translocation and cytotoxicity mediated by GAPDH. Proc. Natl. Acad. Sci. USA 103: 3405-3409 [Abstract] [Full Text]  
• Matsumoto, G., Kim, S., Morimoto, R. I. (2006). Huntingtin and Mutant SOD1 Form Aggregate Structures with Distinct Molecular Properties in Human Cells. J. Biol. Chem. 281: 4477-4485 [Abstract] [Full Text]  
• Albertini, V., Jain, A., Vignati, S., Napoli, S., Rinaldi, A., Kwee, I., Nur-e-Alam, M., Bergant, J., Bertoni, F., Carbone, G. M., Rohr, J., Catapano, C. V. (2006). Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.. Nucleic Acids Res 34: 1721-1734 [Abstract] [Full Text]  
• Shin, J.-Y., Fang, Z.-H., Yu, Z.-X., Wang, C.-E., Li, S.-H., Li, X.-J. (2005). Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171: 1001-1012 [Abstract] [Full Text]  
• Sun, X., Wang, Y., Qing, H., Christensen, M. A., Liu, Y., Zhou, W., Tong, Y., Xiao, C., Huang, Y., Zhang, S., Liu, X., Song, W. (2005). Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J. 19: 739-749 [Abstract] [Full Text]  
• Chiang, M.-C., Lee, Y.-C., Huang, C.-L., Chern, Y. (2005). cAMP-response Element-binding Protein Contributes to Suppression of the A2A Adenosine Receptor Promoter by Mutant Huntingtin with Expanded Polyglutamine Residues. J. Biol. Chem. 280: 14331-14340 [Abstract] [Full Text]  
• Zucker, B., Luthi-Carter, R., Kama, J. A., Dunah, A. W., Stern, E. A., Fox, J. H., Standaert, D. G., Young, A. B., Augood, S. J. (2005). Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet 14: 179-189 [Abstract] [Full Text]  
• Ferrante, R. J., Ryu, H., Kubilus, J. K., D'Mello, S., Sugars, K. L., Lee, J., Lu, P., Smith, K., Browne, S., Beal, M. F., Kristal, B. S., Stavrovskaya, I. G., Hewett, S., Rubinsztein, D. C., Langley, B., Ratan, R. R. (2004). Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease. J. Neurosci. 24: 10335-10342 [Abstract] [Full Text]  
• Li, S.-H., Li, X.-J. (2004). Huntington and its Role in Neuronal Degeneration. Neuroscientist 10: 467-475 [Abstract]  
• Trushina, E., Dyer, R. B., Badger, J. D. II, Ure, D., Eide, L., Tran, D. D., Vrieze, B. T., Legendre-Guillemin, V., McPherson, P. S., Mandavilli, B. S., Van Houten, B., Zeitlin, S., McNiven, M., Aebersold, R., Hayden, M., Parisi, J. E., Seeberg, E., Dragatsis, I., Doyle, K., Bender, A., Chacko, C., McMurray, C. T. (2004). Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro. Mol. Cell. Biol. 24: 8195-8209 [Abstract] [Full Text]  
• Schilling, G., Savonenko, A. V., Klevytska, A., Morton, J. L., Tucker, S. M., Poirier, M., Gale, A., Chan, N., Gonzales, V., Slunt, H. H., Coonfield, M. L., Jenkins, N. A., Copeland, N. G., Ross, C. A., Borchelt, D. R. (2004). Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum Mol Genet 13: 1599-1610 [Abstract] [Full Text]  
• Tanaka, K., Shouguchi-Miyata, J., Miyamoto, N., Ikeda, J.-E (2004). Novel Nuclear Shuttle Proteins, HDBP1 and HDBP2, Bind to Neuronal Cell-specific cis-Regulatory Element in the Promoter for the Human Huntington's Disease Gene. J. Biol. Chem. 279: 7275-7286 [Abstract] [Full Text]  
• Obrietan, K., Hoyt, K. R. (2004). CRE-Mediated Transcription Is Increased in Huntington's Disease Transgenic Mice. J. Neurosci. 24: 791-796 [Abstract] [Full Text]  
• Christensen, M. A., Zhou, W., Qing, H., Lehman, A., Philipsen, S., Song, W. (2004). Transcriptional Regulation of BACE1, the {beta}-Amyloid Precursor Protein {beta}-Secretase, by Sp1. Mol. Cell. Biol. 24: 865-874 [Abstract] [Full Text]  
• Ferrante, R. J., Kubilus, J. K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi-Carter, R., Hersch, S. M. (2003). Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice. J. Neurosci. 23: 9418-9427 [Abstract] [Full Text]  
• Michalik, A., Van Broeckhoven, C. (2003). Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 12: R173-186 [Abstract] [Full Text]  
• Zhou, H., Cao, F., Wang, Z., Yu, Z.-X., Nguyen, H.-P., Evans, J., Li, S.-H., Li, X.-J. (2003). Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J. Cell Biol. 163: 109-118 [Abstract] [Full Text]  
• Li, H., Wyman, T., Yu, Z.-X., Li, S.-H., Li, X.-J. (2003). Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 12: 2021-2030 [Abstract] [Full Text]  
• Li, S.-H., Yu, Z.-X., Li, C.-L., Nguyen, H.-P., Zhou, Y.-X., Deng, C., Li, X.-J. (2003). Lack of Huntingtin-Associated Protein-1 Causes Neuronal Death Resembling Hypothalamic Degeneration in Huntington's Disease. J. Neurosci. 23: 6956-6964 [Abstract] [Full Text]  
• Ryu, H., Lee, J., Zaman, K., Kubilis, J., Ferrante, R. J., Ross, B. D., Neve, R., Ratan, R. R. (2003). Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath Transcription Factors in Cortical Neurons. J. Neurosci. 23: 3597-3606 [Abstract] [Full Text]  
• Ryu, H., Lee, J., Olofsson, B. A., Mwidau, A., Dedeoglu, A., Escudero, M., Flemington, E., Azizkhan-Clifford, J., Ferrante, R. J., Ratan, R. R. (2003). Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. USA 100: 4281-4286 [Abstract] [Full Text]  
• Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., Steffan, J. S., Marsh, J. L., Thompson, L. M., Lewis, C. M., Marks, P. A., Bates, G. P. (2003). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 100: 2041-2046 [Abstract] [Full Text]  
• Jiang, H., Nucifora, F. C. Jr, Ross, C. A., DeFranco, D. B. (2003). Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 12: 1-12 [Abstract] [Full Text]  
• Kazemi-Esfarjani, P., Benzer, S. (2002). Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum Mol Genet 11: 2657-2672 [Abstract] [Full Text]  
• Fossale, E., Wheeler, V. C., Vrbanac, V., Lebel, L.-A., Teed, A., Mysore, J. S., Gusella, J. F., MacDonald, M. E., Persichetti, F. (2002). Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum Mol Genet 11: 2233-2241 [Abstract] [Full Text]  
• Luthi-Carter, R., Hanson, S. A., Strand, A. D., Bergstrom, D. A., Chun, W., Peters, N. L., Woods, A. M., Chan, E. Y., Kooperberg, C., Krainc, D., Young, A. B., Tapscott, S. J., Olson, J. M. (2002). Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11: 1911-1926 [Abstract] [Full Text]  
• Chan, E. Y.W., Luthi-Carter, R., Strand, A., Solano, S. M., Hanson, S. A., DeJohn, M. M., Kooperberg, C., Chase, K. O., DiFiglia, M., Young, A. B., Leavitt, B. R., Cha, J.-H. J., Aronin, N., Hayden, M. R., Olson, J. M. (2002). Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum Mol Genet 11: 1939-1951 [Abstract] [Full Text]  
• Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., Olson, J. M., Cattaneo, E. (2002). Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11: 1953-1965 [Abstract] [Full Text]  
• Dunah, A. W., Jeong, H., Griffin, A., Kim, Y.-M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., Krainc, D. (2002). Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease. Science 296: 2238-2243 [Abstract] [Full Text]  
• Yu, Z.-X., Li, S.-H., Nguyen, H.-P., Li, X.-J. (2002). Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet 11: 905-914 [Abstract] [Full Text]